{"count": 7, "results": [{"_id": "35266419", "pmid": 35266419, "title": "Co-encapsulation of metformin and ginger into the liposomes: in vitro characterization and in vivo anti-psoriasis evaluation.", "journal": "Drug Dev Ind Pharm", "authors": ["Jenabikordi K", "Zadeh BSM", "Rezaie A"], "date": "2021-09-01T00:00:00Z", "doi": "10.1080/03639045.2021.2001488", "meta_date_publication": "2021 Sep", "meta_volume": "47", "meta_issue": "9", "meta_pages": "1447-1458", "score": 50257.54, "text_hl": "Optimized liposome has indicated its ability in localization of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ at the skin may by improving the impaired @<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@psoriatic@@@ skin barrier. ", "citations": {"NLM": "Jenabikordi K, Zadeh BSM, Rezaie A. Co-encapsulation of metformin and ginger into the liposomes: in vitro characterization and in vivo anti-psoriasis evaluation. Drug Dev Ind Pharm. 2021 Sep;47(9):1447-1458. PMID: 35266419", "BibTeX": "@article{35266419, title={Co-encapsulation of metformin and ginger into the liposomes: in vitro characterization and in vivo anti-psoriasis evaluation.}, author={Jenabikordi K and Zadeh BSM and Rezaie A}, journal={Drug Dev Ind Pharm}, volume={47}, number={9}, pages={1447-1458}}"}}, {"_id": "32905192", "pmid": 32905192, "pmcid": "PMC7466800", "title": "Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis", "journal": "BMC Rheumatol", "authors": ["Mantravadi S", "George M", "Brensinger C", "Du M", "Baker JF", "Ogdie A"], "date": "2020-09-02T00:00:00Z", "doi": "10.1186/s41927-020-00138-3", "meta_date_publication": "2020", "meta_volume": "4", "meta_issue": "", "meta_pages": "39", "score": 50254.227, "text_hl": "Among 10,389 drug initiations in 9541 @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@PsA@@@, @DISEASE_Arthritis_Rheumatoid @DISEASE_MESH:D001172 @@@RA@@@, or @DISEASE_Spondylitis_Ankylosing @DISEASE_MESH:D013167 @@@AS@@@, and available HbA1c values, HbA1c was >=7 at baseline in 254 (35%) TNFi initiations, 361(37%) @CHEMICAL_Methotrexate @CHEMICAL_MESH:D008727 @@@MTX@@@ initiations, and 2144 (50%) @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ initiations. ", "citations": {"NLM": "Mantravadi S, George M, Brensinger C, Du M, Baker JF, Ogdie A. Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis BMC Rheumatol. 2020;4():39. PMID: 32905192", "BibTeX": "@article{32905192, title={Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis}, author={Mantravadi S and George M and Brensinger C and Du M and Baker JF and Ogdie A}, journal={BMC Rheumatol}, volume={4}, pages={39}}"}}, {"_id": "34490702", "pmid": 34490702, "title": "Association between alpha-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.", "journal": "Int J Clin Pract", "authors": ["Huang PJ", "Wei JC", "Liu YT", "Lin CH", "Lin CC", "Chen HH"], "date": "2021-11-01T00:00:00Z", "doi": "10.1111/ijcp.14819", "meta_date_publication": "2021 Nov", "meta_volume": "75", "meta_issue": "11", "meta_pages": "e14819", "score": 50253.2, "text_hl": "AIMS: To investigate the association between the use of alpha-glucosidase inhibitors (AGIs) and the risk of @<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@psoriatic disease@@@ (ie, @DISEASE_Psoriasis @DISEASE_MESH:D011565 @@@psoriasis@@@ and @<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@psoriatic arthritis@@@) in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@ (@DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@) treated with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Huang PJ, Wei JC, Liu YT, Lin CH, Lin CC, Chen HH. Association between alpha-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study. Int J Clin Pract. 2021 Nov;75(11):e14819. PMID: 34490702", "BibTeX": "@article{34490702, title={Association between alpha-glucosidase inhibitor use and psoriatic disease risk in patients with type 2 diabetes mellitus: A population-based cohort study.}, author={Huang PJ and Wei JC and Liu YT and Lin CH and Lin CC and Chen HH}, journal={Int J Clin Pract}, volume={75}, number={11}, pages={e14819}}"}}, {"_id": "32674107", "pmid": 32674107, "title": "Combination of LMT-28 and Metformin Improves Beneficial Anti-Inflammatory Effect in Collagen-Induced Arthritis.", "journal": "Pharmacology", "authors": ["Park YH", "Jang YJ", "Choi Y", "Lee K", "Kim HJ", "Cho O", "Lee HR", "Heo TH"], "date": "2021-01-01T00:00:00Z", "doi": "10.1159/000507451", "meta_date_publication": "2021", "meta_volume": "106", "meta_issue": "1-2", "meta_pages": "53-59", "score": 50247.273, "text_hl": "The combination of @CHEMICAL_LMT_28 @CHEMICAL_MESH:C000600815 @@@LMT-28@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ ameliorated the @<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@arthritic@@@ score better than individual treatments. ", "citations": {"NLM": "Park YH, Jang YJ, Choi Y, Lee K, Kim HJ, Cho O, Lee HR, Heo TH. Combination of LMT-28 and Metformin Improves Beneficial Anti-Inflammatory Effect in Collagen-Induced Arthritis. Pharmacology. 2021;106(1-2):53-59. PMID: 32674107", "BibTeX": "@article{32674107, title={Combination of LMT-28 and Metformin Improves Beneficial Anti-Inflammatory Effect in Collagen-Induced Arthritis.}, author={Park YH and Jang YJ and Choi Y and Lee K and Kim HJ and Cho O and Lee HR and Heo TH}, journal={Pharmacology}, volume={106}, number={1-2}, pages={53-59}}"}}, {"_id": "40876504", "pmid": 40876504, "title": "Metformin treatment protects mice from glucose-promoted psoriasiform dermatitis through enrichment of Akkermansia muciniphila with modulation of bacterial tryptophan metabolites.", "journal": "J Invest Dermatol", "authors": ["Lai Y", "Jiang Z", "Qiu X", "Hong D", "Liu X", "Liu S", "Wu X", "Guo S", "Bloomstein JD", "Hwang ST", "Tan G", "Wang L", "Zhang Z", "Shi Z"], "date": "2025-08-26T00:00:00Z", "doi": "10.1016/j.jid.2025.08.017", "meta_date_publication": "2025 Aug 26", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50243.707, "text_hl": "Nonetheless, the role of gut microbiota in the anti-@<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@psoriatic@@@ effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ remains unclear. ", "citations": {"NLM": "Lai Y, Jiang Z, Qiu X, Hong D, Liu X, Liu S, Wu X, Guo S, Bloomstein JD, Hwang ST, Tan G, Wang L, Zhang Z, Shi Z. Metformin treatment protects mice from glucose-promoted psoriasiform dermatitis through enrichment of Akkermansia muciniphila with modulation of bacterial tryptophan metabolites. J Invest Dermatol. 2025 Aug 26;():. PMID: 40876504", "BibTeX": "@article{40876504, title={Metformin treatment protects mice from glucose-promoted psoriasiform dermatitis through enrichment of Akkermansia muciniphila with modulation of bacterial tryptophan metabolites.}, author={Lai Y and Jiang Z and Qiu X and Hong D and Liu X and Liu S and Wu X and Guo S and Bloomstein JD and Hwang ST and Tan G and Wang L and Zhang Z and Shi Z}, journal={J Invest Dermatol}}"}}, {"_id": "27930978", "pmid": 27930978, "title": "Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis.", "journal": "Biomed Pharmacother", "authors": ["El-Gharabawy RM", "Ahmed AS", "Al-Najjar AH"], "date": "2017-01-01T00:00:00Z", "doi": "10.1016/j.biopha.2016.11.105", "meta_date_publication": "2017 Jan", "meta_volume": "85", "meta_issue": "", "meta_pages": "141-147", "score": 50049.58, "text_hl": "@DISEASE_Psoriasis @DISEASE_MESH:D011565 @@@Psoriasis@@@ @SPECIES_9606 @@@patients@@@ treated with anti-@<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@psoriatic@@@ treatment and oral @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (850mg twice daily) and 5. ", "citations": {"NLM": "El-Gharabawy RM, Ahmed AS, Al-Najjar AH. Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis. Biomed Pharmacother. 2017 Jan;85():141-147. PMID: 27930978", "BibTeX": "@article{27930978, title={Mechanism of action and effect of immune-modulating agents in the treatment of psoriasis.}, author={El-Gharabawy RM and Ahmed AS and Al-Najjar AH}, journal={Biomed Pharmacother}, volume={85}, pages={141-147}}"}}, {"_id": "30779846", "pmid": 30779846, "title": "Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study.", "journal": "J Clin Endocrinol Metab", "authors": ["Su YJ", "Chen TH", "Hsu CY", "Chiu WT", "Lin YS", "Chi CC"], "date": "2019-08-01T00:00:00Z", "doi": "10.1210/jc.2018-02526", "meta_date_publication": "2019 Aug 1", "meta_volume": "104", "meta_issue": "8", "meta_pages": "3279-3286", "score": 50045.285, "text_hl": "OBJECTIVE: To investigate the real-world safety of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Arthritis_Psoriatic</m> @DISEASE_MESH:D015535 @@@psoriatic@@@ @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes mellitus@@@ (@DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@). ", "citations": {"NLM": "Su YJ, Chen TH, Hsu CY, Chiu WT, Lin YS, Chi CC. Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3279-3286. PMID: 30779846", "BibTeX": "@article{30779846, title={Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study.}, author={Su YJ and Chen TH and Hsu CY and Chiu WT and Lin YS and Chi CC}, journal={J Clin Endocrinol Metab}, volume={104}, number={8}, pages={3279-3286}}"}}]}